AUDICOR Heart Failure Management System Granted U.S. Food and Drug Administration Breakthrough Device Designation

CathWorks FFRangio™ System Receives National Reimbursement Approval in Japan

CathWorks announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the application to provide reimbursement for the CathWorks FFRangio™ System,...

Levine Leichtman Capital Partners Sells FlexXray

Levine Leichtman Capital Partners ("LLCP"), a Los Angeles-based private equity firm, announced today that it has sold its portfolio company FlexXray Holdings, LLC ("FlexXray" or...

February 23, 2021

AUDICOR heart failure management system uses clinically tested algorithms to detect the risk of decompensation at home in patients who have been previously hospitalized for heart failure reports Inovise Medical.

Michael Mirro, MD, Director of the Parkview Mirro Center for Research and Innovation, and Clinical Professor of Medicine at Indiana University, commented, “This technology promises to enhance the management of heart failure patients and keep them out of the hospital. Early detection of potential problems outside of the hospital can allow clinicians to modify the patients’ therapeutic regimens and maintain their stable condition.”

The AUDICOR heart failure management system is non-invasive and assesses the mechanical efficiency, as well as the electrical activity, of the heart. Signals are acquired through a hand-held device that connects to a smartphone for analysis in the cloud. This analysis of the signals produces proprietary cardiac acoustic biomarkers, which have been shown to provide actionable data to optimize therapy and improve patient outcomes.

Physicians receive notifications based on biomarker trends and values, allowing them to modify patient therapy (e.g., change drug dosage) before there is a significant deterioration of heart failure status requiring hospitalization.

“The most significant advantages of this new technology are enhanced ease of use, eliminated risks of surgical complications, and significantly reduced costs compared to permanently implanted physiologic sensors currently on the market,” said Peter Bauer, Ph.D., CEO of Inovise Medical

spot_img

DON'T MISS

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.